August 23, 2023
Exclusive: Bloomberg Technology’s Ed Ludlow Interviews Cellares’ CEO and Co-founder, Fabian Gerlinghaus on Company’s Massive $255M Series C Up-Round
Related News
-
January 12, 2026IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares’ Automated Platform
-
January 12, 2026
Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands
-
January 08, 2026
Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy
